Please provide your email address to receive an email when new articles are posted on . Use of budesonide before FMT did not increase donor microbiota engraftment or clinical response. Differences in ...
Please provide your email address to receive an email when new articles are posted on . Padagis received FDA approval of its abbreviated new drug application for budesonide 2mg rectal foam for the ...
LAVAL, QE / ACCESSWIRE / September 12, 2023 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is pleased to announce that following its approval by Health Canada the new treatment Pr UCERIS ® ...
RALEIGH, N.C.--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Food and Drug Administration (FDA) has accepted for filing a New Drug Application (NDA) for ...
Credit: Getty Images. Padagis was granted 180 days of Competitive Generic Therapy exclusivity. A generic version of Uceris ® (budesonide 2mg rectal foam) has been made available by Padagis. Budesonide ...
LAVAL, QC / ACCESSWIRE / May 23, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced additional Canadian public drug plan listings for Pr ...
UCERIS is now available for patients through the public drug plans of five Canadian provinces: Ontario, Quebec, Saskatchewan, New Brunswick and Nova Scotia. These first public drug plan listings for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results